MedTrace Logo

Africa Ready Malaria Screening

NCT06153862 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1640

Last updated 2023-12-01

No results posted yet for this study

Summary

This study aims to develop immuno-analytical assays for testing the titres of malaria antibodies in Ghanaian patients' and/or donors' sera using a recombinantly produced MSP119 fusion protein and/or MSP119-derived synthetic peptides as antigens.

Conditions

Interventions

DIAGNOSTIC_TEST

Immuno analytical assay

The eluted antibodies will be used in immuno-analytical assays, such as ELISA or Western blot, or surface-coated bead-based screening platforms using either recombinantly produced MSP119 fusion protein or synthetic peptides derived from MSP119 as antigens according to standard protocols.

Sponsors & Collaborators

  • Shai-Osudoku District Hospital

    collaborator UNKNOWN

  • Kumasi Technical University

    collaborator UNKNOWN

  • University of Rostock

    collaborator OTHER

  • University of Applied Sciences Bonn-Rhein-Sieg

    collaborator UNKNOWN

  • Hochschule Aalen

    collaborator UNKNOWN

  • University of Ghana

    lead OTHER

Principal Investigators

  • Adjei · Shai-Osudoku District Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-23
Primary Completion
2024-09-30
Completion
2025-09-30

Countries

  • Ghana

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06153862 on ClinicalTrials.gov